Last edition
News about
Sanofi and Cipla Partner to Expand CNS Portfolio Distribution in India
As part of the partnership, Cipla will take on the responsibility of distributing Sanofi India's six CNS brands, including Frisium®, a notable name in the anti-epileptic medication category.
Bridge Biotherapeutics New Venture into Immuno-Oncology with University of Colorado
Bridge Biotherapeutics has forged a research collaboration with Dr. Raul Torres's Lab at the University of Colorado School of Medicine.
AstraZeneca Pharma India Names Vinay Sharma as Business Unit Head for Rare Disease Unit
Sharma is a Post?Graduate in Marketing Management and Business Administration with over 23 years of industry experience.
Teva UK and Closed Loop Medicine Collaborates to Advance Development of Personalised Medicines
Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.
STEMCELL Technologies announce that its new EasySep™ Human Bone Marrow CD138 Positive Selection Kit has been granted de novo classification by the U.S. Food and Drug Administration (FDA) as a first-of-its-kind in vitro diagnostic (IVD) medical device for hematopoietic cell enrichment.
Andelyn Biosciences Partners with Grace Science to Accelerate Development of NGLY1 Gene Therapy
NGLY1 Deficiency is a severe, life-threatening condition characterized by developmental delay, cognitive impairment, movement disorders, and other debilitating neurological symptoms.
Novo Nordisk to Acquire Cardior Pharmaceuticals for up to EUR 1.025 Billion
At the heart of the acquisition is Cardior's lead compound, CDR132L, currently in phase 2 clinical development for the treatment of heart failure.
Poseida Therapeutics Welcomes Syed Rizvi as New Chief Medical Officer
Poseida Therapeutics, Inc. has appointed Syed Rizvi, MD, as Chief Medical Officer effective April 1, 2024.
<br />
Aptamer Sciences Files IND Application for Phase 1 Clinical Trial of AST-201
Aptamer Sciences Inc. has filed for an Investigational New Drug (IND) application for the phase 1 clinical trial of AST-201 with the Korean Ministry of Food and Drug Safety
Scivita Medical Signs Extended Partnership with Boston Scientific
Scivita Medical Technology Co., Ltd. has signed an expanded strategic cooperation arrangement with Boston Scientific.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy